Is Alkermes (ALKS) Pricing Reflect Its Strong Recent Share Price Performance?

• If you are wondering whether Alkermes at US$34.88 is offering good value right now, you are not alone. This article is designed to help you assess that.
• The stock has returned 2.7% over the last 7 days, 25.4% over the last 30 days, 23.4% year to date, 9.3% over 1 year, 28.3% over 3 years and 62.9% over 5 years. This raises fair questions about how the current price lines up with fundamentals.
• These return figures sit against a backdrop of ongoing interest in Alkermes as a Nasdaq listed pharmaceuticals and biotech company, with investors watching how its product portfolio and pipeline positioning influence sentiment. Recent coverage has focused on the company’s role within its sector and how that focus may be shaping expectations around its long term prospects.
• On Simply Wall St’s valuation checks, Alkermes scores 5 out of 6, which suggests several traditional methods point to undervaluation. We will look at these approaches next before finishing with a different way of thinking about what fair value could mean for you.

Find out why Alkermes's 9.3% return over the last year is lagging behind its peers.

Approach 1: Alkermes Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes the cash Alkermes is expected to generate in the future, then discounts those projections back to a single value today. It is essentially asking what those future cash flows are worth in present terms.

Here, the 2 Stage Free Cash Flow to Equity model uses Alkermes’ last twelve months Free Cash Flow of about $497.6 million as a starting point. Analysts provide Free Cash Flow estimates out to 2030, with Simply Wall St extrapolating further beyond the explicit analyst window. For example, projected Free Cash Flow for 2030 is $697.8 million, with intermediate years such as 2026, 2027 and 2028 also modeled in the hundreds of millions of dollars using both analyst inputs and calculated growth rates.

When these projected cash flows are discounted back to today using the DCF approach, Simply Wall St arrives at an estimated intrinsic value of about $103.07 per share. Compared with the current share price of around $34.88, this model suggests Alkermes trades at a 66.2% discount, which points to a wide margin between price and this particular estimate of value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Alkermes is undervalued by 66.2%. Track this in your watchlist or portfolio, or discover 868 more undervalued stocks based on cash flows.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Alkermes.

Approach 2: Alkermes Price vs Earnings

For a profitable company like Alkermes, the P/E ratio is a useful way to think about what you are paying for each dollar of earnings. It ties the share price directly to the business’s current earning power, which is usually a key anchor for many investors.

What counts as a “normal” or “fair” P/E depends on how fast earnings are expected to grow and how risky those earnings appear. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk often points to a lower one.

Alkermes currently trades on a P/E of 17.0x, compared with the Biotechs industry average of about 20.2x and a peer group average of 35.1x. Simply Wall St’s proprietary “Fair Ratio” for Alkermes is 20.1x. This Fair Ratio aims to capture what a reasonable P/E could be for the company given factors like its earnings growth profile, industry, profit margins, market cap and specific risks. Because it is tailored to the company, it can be more informative than a simple comparison with industry or peers alone.

The current P/E of 17.0x sits below the Fair Ratio of 20.1x, which points to Alkermes trading below this customized valuation yardstick.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1414 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your Alkermes Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives.

A Narrative is simply your story for Alkermes, where you connect what you believe about its products, pipeline and risks to your own numbers, such as future revenue, earnings and margins, and then to an assumed fair value.

On Simply Wall St, Narratives sit inside the Community page, where millions of investors use them as an easy tool to link a company’s story to a financial forecast, then compare their Fair Value with today’s Price to help decide whether they are comfortable buying, holding or selling.

Because Narratives update when fresh information appears, such as earnings releases or news, your forecast and Fair Value can adjust automatically without you rebuilding your whole view from scratch.

For Alkermes, one investor might build a Narrative that sees high long term potential and a Fair Value well above US$34.88, while another might assume more conservative revenue growth and margins and arrive at a Fair Value closer to the current price.

Do you think there's more to the story for Alkermes? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com